Last reviewed · How we verify
ANAVEX2-73 oral liquid
ANAVEX2-73 is an oral liquid formulation of a sigma-1 receptor agonist.
ANAVEX2-73 is an oral liquid formulation of a sigma-1 receptor agonist. Used for Alzheimer's disease, Parkinson's disease.
At a glance
| Generic name | ANAVEX2-73 oral liquid |
|---|---|
| Also known as | Blarcamesine |
| Sponsor | Anavex Life Sciences Corp. |
| Drug class | sigma-1 receptor agonist |
| Target | sigma-1 receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
Sigma-1 receptor agonists are a class of compounds that activate the sigma-1 receptor, a protein involved in various cellular processes. ANAVEX2-73 is being investigated for its potential therapeutic effects in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.
Approved indications
- Alzheimer's disease
- Parkinson's disease
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
- ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome (PHASE2, PHASE3)
- ANAVEX2-73 Study in Patients With Rett Syndrome (PHASE3)
- Study of ANAVEX2-73 in Patients With Rett Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ANAVEX2-73 oral liquid CI brief — competitive landscape report
- ANAVEX2-73 oral liquid updates RSS · CI watch RSS
- Anavex Life Sciences Corp. portfolio CI